Cabometyx Norway

Cabometyx in Europe

Contact
This is a promotional website intended for Healthcare Professionals in Norway
Abbreviations
Safety Information
SmPC

CABOMETYX® (cabozantinib) and Renal Cell Carcinoma Guidelines

Current clinical practice guidelines for the management of renal cell carcinoma (RCC) include those produced by the European Society for Medical Oncology (ESMO)12, the European Association of Urology (EAU) 13, and the National Comprehensive Cancer Network (NCCN) 15, updated in 2019.

Cabometyx and the ESMO RCC Guidelines

The only TKI to be given a ‘Grade A’ recommendation in patients who have received prior TKI therapy [I,A] and treatment-naïve patients (intermediate-risk) [II,A]

For more info about the latest ESMO clinical practice guidelines on the diagnosis, treatment and follow-up of renal cell carcinoma:

Cabometyx and the EAU RCC Guidelines

Read about the 2019 update of the EAU guidelines on renal cell carcinoma.

Cabometyx and the NCCN RCC Guidelines

The only TKI to be designated as “preferred” in treatment-naïve patients (intermediate-, poor-risk) and those who have received prior therapy

For more info about NCCN clinical practice guidelines on renal cell carcinoma:
References
© Ipsen Group 2020 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the Norway Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Welcome to Cabometyx.no website. This website is intended for Norway Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.

I AM A NORWEGIAN HEALTHCARE PROFESSIONAL

I AM A EU HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL